Jazz Pharmaceuticals (JAZZ) Jefferies Global Healthcare Conference summary

Business progress and strategic positioning

• Achieved significant progress across commercial, R&D, and corporate development, including integration of the Zymeworks transaction and addition of zanidatamab to the portfolio.

• Confident in full-year revenue guidance of $4.15–$4.4 billion, driven by growth in the sleep portfolio and oncology launches.

• Settled with all 10 ANDA filers for Xywav, securing franchise durability through the next decade.

• Strong financial position enables continued investment in commercial products, pipeline growth, and corporate development.

Oncology portfolio and clinical data highlights

• IMforte study in small cell lung cancer showed statistically and clinically meaningful survival benefits with Zepzelca, with median survival of 16–17 months and favorable safety profile.

• Updated phase 2 GEA data for zanidatamab plus chemotherapy showed median overall survival of 36.5 months and PFS of 15.2 months, supporting confidence in upcoming frontline GEA readout.

• Positive CHMP opinion for zanidatamab in Europe for BTC, with approval expected soon.

• Multiple upcoming oncology launches anticipated over the coming quarters.

Zanidatamab development and differentiation

• Zanidatamab is highly differentiated, showing strong immune activity and receptor internalization, with favorable efficacy in HER2-driven cancers.

• Well tolerated as monotherapy and in combination, with manageable toxicities.

• Ongoing pivotal program in breast cancer patients progressed on Enhertu, with global interest and active site enrollment.

• Exploring expansion into neoadjuvant and adjuvant GEA, colorectal, lung, and pan-tumor indications.

• Pursuing a pan-tumor registrational path, leveraging favorable benefit-risk profile and regulatory precedent.